Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review

  • Lorraine Larsen RosamiliaEmail author
Therapy in Practice


Herpes zoster (HZ) is a common cutaneous entity with protean clinical presentations, management options, complication rates, and prevention strategies, all of which are rife with dogma. During an inpatient consultation for HZ, have you ever been approached by a frantic staff or family member, worried that a pregnant, elderly, or infant contact will be ‘infected’ if they get too close? Have your patients ever asked you about their risk of having HZ twice, or claimed that they have frequent ‘recurrences’? In what timeline should antiviral therapy be employed? Is there evidence for prednisone or gabapentin in acute HZ treatment? Who should be vaccinated against HZ and what are the benefits and risks? In case-based form, these and other complex but common scenarios will be examined using clinical and viral mechanistic clues, along with updated treatment and prevention guidelines, to provide a modern HZ case management compendium, comprehensive of the diverse age and health populations now presenting with this condition.


Compliance with Ethical Standards


No funding was received for the preparation of this article.

Conflict of interest

Dr Rosamilia has no conflicts of interest to declare.


  1. 1.
    Brisson M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Yawn BP, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Kawai K, et al. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Lim HW, et al. The burden of skin disease in the United States. J Am Acad Dermatol. 2017;76(5):958–72.e2.PubMedCrossRefGoogle Scholar
  5. 5.
    Dworkin RH, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Wood MJ, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896–900.PubMedCrossRefGoogle Scholar
  7. 7.
    McKendrick MW, et al. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293:1529–32.CrossRefGoogle Scholar
  8. 8.
    Whitley RJ, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang M, et al. A meta-analysis of therapeutic efficacy and safety of gabapentin in the treatment of postherpetic neuralgia from randomized controlled trials. Biomed Res Int. 2018;2018:7474207.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Feli KH, et al. Update in herpes zoster prevention and the role of dermatologists. J Drugs Dermatol. 2019;18(1):18–22.PubMedGoogle Scholar
  11. 11.
    Nair PA. Herpes zoster: mistaken for radiculopathy and back pain. J Indian Med Assoc. 2012;110(6):399.PubMedGoogle Scholar
  12. 12.
    Böer A, et al. Refining criteria for diagnosis of cutaneous infections caused by herpes viruses through correlation of morphology with molecular pathology. Indian J Dermatol Venereol Leprol. 2006;72(4):270–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Morgan R, King D. Characteristics of patients with shingles admitted to a district general hospital. Postgrad Med J. 1998;74(868):101–3.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Brănişteanu DE, et al. Clinical-epidemiological trends of herpes zoster: a 5-year study. Rev Med Chir Soc Med Nat Iasi. 2014;118(3):817–22.PubMedGoogle Scholar
  15. 15.
    Aggarwal S, Radhakrishnan S. A clinico-epidemiological study of herpes zoster. Med J Armed Forces India. 2016;72(2):175–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Abdul E, Pavithran K. Herpes zoster: a clinical study in 205 patients. Ind J Dermatol. 2011;56:529–32.CrossRefGoogle Scholar
  17. 17.
    Shors T. Herpesviruses: Varicella Zoster Virus (VZV). In: Shors T, editor. Understanding viruses. 2nd ed. Burlington: Jones & Bartlett; 2011. p. 459.Google Scholar
  18. 18.
    CDC Varicella Vaccine Recommendations. Accessed 28 Aug 2019.
  19. 19.
  20. 20.
  21. 21.
    Reynolds MA, et al. Varicella seroprevalence in the US: data from the National Health and Nutrition Examination Survey, 1999–2004. Public Health Rep. 2010;125(6):860–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
  23. 23.
    CDC Shingrix recommendations. Accessed 28 Aug 2019.
  24. 24.
    Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41(2):95–105.PubMedGoogle Scholar
  25. 25.
    Harpaz R, Leung JW. The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among older adults. Clin Infect Dis. 2019;69(2):341–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Ragozzino MW, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Lamont RF, et al. Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG. 2011;118(10):1155–62.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Feder HM, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23:451–7.PubMedCrossRefGoogle Scholar
  30. 30.
    David TJ, Williams ML. Herpes zoster in infancy. Scand J Infect Dis. 1979;11:185–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Forbes H, et al. Quantification of risk factors for herpes zoster: population-based case–control study. BMJ. 2014;348:g2911.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Prabhu S, et al. Childhood herpes zoster: a clustering of ten cases. Indian J Dermatol. 2009;54:62–4.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Katakam BK, et al. A prospective study of herpes zoster in children. Indian J Dermatol. 2016;61:534–9.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Weinmann S, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis. 2013;208:1859–68.PubMedCrossRefGoogle Scholar
  35. 35.
    Weinmann S, et al. Incidence of herpes zoster among children: 2003–2014. Pediatrics. 2019;144(1):e20182917.PubMedCrossRefGoogle Scholar
  36. 36.
    Harpaz R. Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Rev Vaccines. 2019;18(8):793–811.PubMedCrossRefGoogle Scholar
  37. 37.
    Wutzler P, et al. Herpes zoster in the context of varicella vaccination—an equation with several variables. Vaccine. 2018;36(46):7072–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Lewis DJ, et al. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients. Cutis. 2017;100(5):321, 324, 330.Google Scholar
  39. 39.
    Schmader K. Herpes zoster. Ann Intern Med. 2018;169:ITC19–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Tilley DH, et al. Disseminated verrucous varicella zoster with exclusive follicular involvement. Arch Dermatol. 2012;148(3):405–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Wauters O, et al. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol. 2012;66(6):e217–27.PubMedCrossRefGoogle Scholar
  42. 42.
    Prelog M, et al. Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients. Vaccine. 2013;31:2420–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Gilbert L, et al. Herpes zoster rates continue to decline in people living with human immunodeficiency virus but remain higher than rates reported in the general US population. Clin Infect Dis. 2019;69(1):155–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Insinga RP, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–53.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57.PubMedGoogle Scholar
  46. 46.
    Ljubojević HS, et al. Genital herpes zoster as possible indicator of HIV infection. Acta Dermatovenerol Croat. 2018;26(4):337–8.Google Scholar
  47. 47.
    Dayan RR, Peleg R. Herpes zoster—typical and atypical presentations. Postgrad Med. 2017;129(6):567–71.PubMedCrossRefGoogle Scholar
  48. 48.
    Chughtai K, et al. Topical 5-fluorouracil associated skin reaction. Oxf Med Case Rep. 2017;2017(8):omx043.CrossRefGoogle Scholar
  49. 49.
    Wilson DA, et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50(12):4120–2.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Dobec M, et al. Serology and serum DNA detection in shingles. Swiss Med Wkly. 2008;138(3–4):47–51.PubMedGoogle Scholar
  51. 51.
    Balfour HH, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448–53.PubMedCrossRefGoogle Scholar
  52. 52.
    Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2 Suppl):S3–12.PubMedCrossRefGoogle Scholar
  53. 53.
    Tyring S, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:89–96.PubMedCrossRefGoogle Scholar
  54. 54.
    Beutner KR, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546–53.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Chen N, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.Google Scholar
  56. 56.
    Stein GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc (Wash). 1997;37(2):157–63.CrossRefGoogle Scholar
  57. 57.
    Ormrod D, Goa K. Valaciclovir: a review of its use in the management of herpes zoster. Drugs. 2000;59(6):1317–40.PubMedCrossRefGoogle Scholar
  58. 58.
    Madkan VK, et al. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. J Cutan Med Surg. 2007;11(3):89–98.PubMedCrossRefGoogle Scholar
  59. 59.
    Barnabas RV, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis. 2016;213(4):551–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Chen N, et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2010;12:CD005582.Google Scholar
  61. 61.
    Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2013;3:CD005582.Google Scholar
  62. 62.
    Dworkin RH, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009;142(3):209–17.PubMedCrossRefGoogle Scholar
  63. 63.
    Bulilete O, et al. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial. PLoS One. 2019;14(6):e0217335.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Ghaznawi N, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology. 2011;118(11):2242–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2–3):241–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Thyregod HG, et al. Natural history of pain following herpes zoster. Pain. 2007;128(1–2):148–56.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhu SM, et al. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10(8):625–30.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139–45.PubMedCrossRefGoogle Scholar
  69. 69.
    Kawai K, et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Hempenstall K, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Johnson P, et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33(1):35–44.PubMedCrossRefGoogle Scholar
  72. 72.
    Nagasako EM, et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol. 2002;46(6):834–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Drolet M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Galer BS, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Lin CS, et al. Interventional treatments for postherpetic neuralgia: a systematic review. Pain Physician. 2019;22(3):209–28.PubMedGoogle Scholar
  77. 77.
  78. 78.
    CDC Zostavax recommendations. Accessed 28 Aug 2019.
  79. 79.
  80. 80.
    Opstelten W, et al. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009;27(2):192–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Schmader KE, Shingles Prevention Study Group, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Vink P et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis. 2019. Scholar
  83. 83.
    Vink P, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Berkowitz EM, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87.PubMedCrossRefGoogle Scholar
  85. 85.
    Bastidas A, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33.PubMedCrossRefGoogle Scholar
  86. 86.
    Dooling KL, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–8.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Dagnew AF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000.PubMedCrossRefGoogle Scholar
  88. 88.
    Baumrin E, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102–10.PubMedCrossRefGoogle Scholar
  89. 89.
    Failla V, et al. Herpes zoster in patients treated with biologicals. Dermatology. 2012;224(3):251–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Zaal MJ, et al. Longitudinal analysis of varicella-zoster virus DNA on the ocular surface associated with herpes zoster ophthalmicus. Am J Ophthalmol. 2001;131:25–9.PubMedCrossRefGoogle Scholar
  91. 91.
    CDC Preventing VZV Transmission in Healthcare Settings. 2019. Accessed 28 Aug 2019.
  92. 92.
    Tseng HF, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis. 2014;58(8):1125–8.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Guffey DJ. Herpes zoster following varicella vaccination in children. Cutis. 2017;99(3):207–11.PubMedGoogle Scholar
  94. 94.
    Peterson N, Goodman S, Peterson M, et al. Herpes zoster in children. Cutis. 2016;98:94–5.PubMedGoogle Scholar
  95. 95.
    Lopez AS, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis. 2008;197(5):646–53.PubMedCrossRefGoogle Scholar
  96. 96.
    Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.PubMedGoogle Scholar
  97. 97.
    Goulleret N, et al. Safety profile of live varicella virus vaccine (Oka/Merck): 5-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine. 2010;28(36):5878–82.PubMedCrossRefGoogle Scholar
  98. 98.
    Pryde PG. Varicella zoster virus in pregnancy. In: Craigo SD, Baker ER, editors. Medical Complications in Pregnancy. NewYork: McGraw-Hill; 2005. p. 383–98.Google Scholar
  99. 99.
    Müllegger RR, et al. Skin infections in pregnancy. Clin Dermatol. 2016;34(3):368–77.PubMedCrossRefGoogle Scholar
  100. 100.
    Hayward K, et al. Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol. 2018;38(7):887–94.PubMedCrossRefGoogle Scholar
  101. 101.
    Sauerbrei A, Wutzler P. Placental boost to varicella-zoster antibodies in the newborn. J Perinat Med. 2002;30(4):345–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Casanova RG, et al. Herpes zoster in immunocompetent pregnant women and their perinatal outcome. Ginecol Obstet Mex. 2004;72:63–7.Google Scholar
  103. 103.
    Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010;304(8):859–66.PubMedCrossRefGoogle Scholar
  104. 104.
    Schafer R, et al. Herpes zoster in pregnancy. J Midwifery Womens Health. 2019;64(2):230–5.PubMedCrossRefGoogle Scholar
  105. 105.
    Hernandez PO, et al. Family history and herpes zoster risk in the era of shingles vaccination. J Clin Virol. 2011;52(4):344–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyGeisinger Health System-Scenery ParkState CollegeUSA

Personalised recommendations